Search

Rose bengal I-131

Enzalutamide

[L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.

Coagulation Factor IX (Recombinant)

Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B). … It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell

Favipiravir

Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. … [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for

Pretomanid

It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … [A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB.

Ensitrelvir

Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

Sugemalimab

[L32868] Sugemalimab was under investigation in the clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma). … [L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology.

Masoprocol

It also serves as an antioxidant in fats and oils. [PubChem]

Bebtelovimab

in the US. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

Dexmedetomidine

An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.